Morgan Stanley Chembio Diagnostics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.25 - $0.45 $797 - $1,435	-3,190 Reduced 68.06%	1,497 $0
Q4 2022 Feb 14, 2023	SELL	$0.2 - $0.33 $310 - $512	-1,552 Reduced 24.88%	4,687 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $1.1 $226 - $711	-647 Reduced 9.4%	6,239 $2,000
Q2 2022 Oct 27, 2022	SELL	$0.45 - $0.8 $2,212 - $3,932	-4,916 Reduced 41.65%	6,886 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.45 - $0.8 $2,212 - $3,932	-4,916 Reduced 41.65%	6,886 $5,000
Q1 2022 Oct 27, 2022	BUY	$0.66 - $1.23 $3,244 - $6,046	4,916 Added 71.39%	11,802 $9,000
Q1 2022 May 13, 2022	SELL	$0.66 - $1.23 $4,817 - $8,977	-7,299 Reduced 38.21%	11,802 $9,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $2.55 $112,293 - $262,706	-103,022 Reduced 84.36%	19,101 $21,000
Q3 2021 Nov 15, 2021	BUY	$2.06 - $5.34 $251,573 - $652,136	122,123 New	122,123 $305,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.